\-\ Texto\\:\\ \ \(0\)\
\-\ afb\\ negative\ \(0\)\
\-\ lyme\\ ab\\ negative\ \(0\)\
\-\ fungal\\ culture\\ negative\ \(0\)\
\-\ ace\\ 55\\;\\ normal\\ 9\\-67\\.\\ \\ per\\ report\\,\\ patient\\ had\\ a\\ positive\\ ena\\ from\\ outside\\ facility\\.\ \(0\)\
\-\ patient\\ was\\ treated\\ with\\ a\\ tapering\\ dose\\ of\\ prednisone\\ and\\ is\\ being\\ followed\\ by\\ pulmonary\\ clinic\\.\ \(0\)\
\-\ plain\\ chest\\ films\\ demonstrate\\ bilateral\\ hilar\\ lymphadenopathy\\ with\\ right\\ paratracheal\\ lymphadenpathy\\ suggestive\\ of\\ sarcoid\\.\\ \\ no\\ pneumothorax\\ or\\ pleural\\ effusion\ \(0\)\
\-\ seen\\.\\ \\ pulmonary\\ vasculature\\ demonstrates\\ normal\\ caliber\\ and\\ distribution\\.\\ \\ surrounding\\ soft\\ tissues\\ and\\ osseous\\ structures\\ are\\ unremarkable\\.\\ \\ cardiac\\ silhouette\\ is\\ normal\\.\ \(0\)\
\-\ sarcoid\ \(163\)\
\-\ sarcoid\ \(163\)\
\-\ lymphoma\ \(373\)\
\-\ tuberculosis\\ or\\ other\\ oppurtunistic\\/fungal\\ disease\ \(0\)\
\-\ sjogren\\â\\€\\™s\\ syndrome\\ with\\ coexistent\\ adenopathy\ \(0\)\
\-\ patient\\ is\\ a\\ 42\\-year\\ african\\ american\\ active\\ duty\\ first\\ sergeant\\.\\ \\ patient\\ presented\\ with\\ bilateral\\ parotitis\\,\\ conjunctivitis\\,\\ xerostomia\\ and\\ shortness\\ of\\ breath\\.\ \(0\)\
\-\ sarcoid\\ is\\ a\\ systemic\\ disorder\\ of\\ unkown\\ etiology\\ characterized\\ by\\ non\\-caseating\\ granulomatous\\ inflammation\\,\\ particularly\\ of\\ the\\ lungs\\.\\ \\ onset\\ of\\ the\\ disease\\ is\\ most\\ common\\ during\\ the\\ third\\ and\\ fourth\\ decades\\.\\ \\ it\\ is\\ more\\ common\\ in\\ african\\ americans\\ and\\ women\\.\\ \\ the\\ chest\\ radiograph\\ will\\ be\\ abnormal\\ in\\ a\\ majority\\ of\\ patients\\ at\\ some\\ point\\ in\\ their\\ disease\\.\\ \\ the\\ chest\\ radiographs\\ of\\ this\\ patient\\ demonstrated\\ the\\ classic\\ radiographic\\ appearance\\ of\\ sarcoid\\,\\ which\\ is\\ right\\ paratracheal\\ and\\ symmetric\\ bilateral\\ hilar\\ lymph\\ node\\ enlargement\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ sarcoid\\:\\ 0\\.3805172318588725\ \(0\)\
\-\ paratracheal\\:\\ 0\\.17978747249192892\ \(0\)\
\-\ is\\:\\ 0\\.1555603490887611\ \(0\)\
\-\ negative\\:\\ 0\\.1507143526189318\ \(0\)\
\-\ hilar\\:\\ 0\\.14881951468876736\ \(0\)\
\-\ african\\:\\ 0\\.14658690544213537\ \(0\)\
\-\ fungal\\:\\ 0\\.14527555953006424\ \(0\)\
\-\ of\\:\\ 0\\.14292258475432776\ \(0\)\
\-\ patient\\:\\ 0\\.13196671023362713\ \(0\)\
\-\ bilateral\\:\\ 0\\.1308356469917723\ \(0\)\
\-\ lymphadenpathy\\:\\ 0\\.129773177193118\ \(0\)\
\-\ xerostomia\\:\\ 0\\.129773177193118\ \(0\)\
\-\ chest\\:\\ 0\\.12850194009936605\ \(0\)\
\-\ sergeant\\:\\ 0\\.12400519889640615\ \(0\)\
\-\ parotitis\\:\\ 0\\.12400519889640615\ \(0\)\
\-\ ena\\:\\ 0\\.11991275316661895\ \(0\)\
\-\ unkown\\:\\ 0\\.11991275316661895\ \(0\)\
\-\ and\\:\\ 0\\.11737755762959648\ \(0\)\
\-\ coexistent\\:\\ 0\\.11673840564498655\ \(0\)\
\-\ conjunctivitis\\:\\ 0\\.11005232914011992\ \(0\)\
\-\ sjogren\\:\\ 0\\.10837679657319525\ \(0\)\
\-\ americans\\:\\ 0\\.10837679657319525\ \(0\)\
\-\ disease\\:\\ 0\\.10218903193053039\ \(0\)\
\-\ normal\\:\\ 0\\.09939644501589516\ \(0\)\
\-\ pulmonary\\:\\ 0\\.09892678673574999\ \(0\)\
\-\ afb\\:\\ 0\\.0985163725466962\ \(0\)\
\-\ ace\\:\\ 0\\.09774723470323156\ \(0\)\
\-\ the\\:\\ 0\\.09715169283552538\ \(0\)\
\-\ tapering\\:\\ 0\\.09701755759198845\ \(0\)\
\-\ ab\\:\\ 0\\.09384321007035604\ \(0\)\
\-\ common\\:\\ 0\\.09204032168762788\ \(0\)\
\-\ decades\\:\\ 0\\.0917318486949854\ \(0\)\
\-\ lyme\\:\\ 0\\.08905669572061939\ \(0\)\
\-\ prednisone\\:\\ 0\\.08548160099856474\ \(0\)\
\-\ caliber\\:\\ 0\\.08516893819625641\ \(0\)\
\-\ silhouette\\:\\ 0\\.0828879702234853\ \(0\)\
\-\ facility\\:\\ 0\\.08047105706062277\ \(0\)\
\-\ vasculature\\:\\ 0\\.07981938961914108\ \(0\)\
\-\ culture\\:\\ 0\\.07859930641942266\ \(0\)\
\-\ duty\\:\\ 0\\.07694544268356372\ \(0\)\
\-\ particularly\\:\\ 0\\.0766026409190409\ \(0\)\
\-\ dose\\:\\ 0\\.07578012370771287\ \(0\)\
\-\ characterized\\:\\ 0\\.0745556620577155\ \(0\)\
\-\ majority\\:\\ 0\\.0737018707681811\ \(0\)\
\-\ women\\:\\ 0\\.07302754619698626\ \(0\)\
\-\ fourth\\:\\ 0\\.0727665189680458\ \(0\)\
\-\ granulomatous\\:\\ 0\\.07213416664812496\ \(0\)\
\-\ systemic\\:\\ 0\\.07201100064198729\ \(0\)\
\-\ tuberculosis\\:\\ 0\\.07141067591873367\ \(0\)\
\-\ pneumothorax\\:\\ 0\\.07072220682054281\ \(0\)\
\-\ 55\\:\\ 0\\.069748212332833\ \(0\)\
\-\ node\\:\\ 0\\.069748212332833\ \(0\)\
\-\ symmetric\\:\\ 0\\.06954053587304551\ \(0\)\
\-\ american\\:\\ 0\\.06923459752600022\ \(0\)\
\-\ by\\:\\ 0\\.06892021958071148\ \(0\)\
\-\ distribution\\:\\ 0\\.06883665312035488\ \(0\)\
\-\ disorder\\:\\ 0\\.06864177904767182\ \(0\)\
\-\ report\\:\\ 0\\.06835438372064609\ \(0\)\
\-\ clinic\\:\\ 0\\.06835438372064609\ \(0\)\
\-\ adenopathy\\:\\ 0\\.06825986121445148\ \(0\)\
\-\ per\\:\\ 0\\.06734765229838828\ \(0\)\
\-\ their\\:\\ 0\\.06734765229838828\ \(0\)\
\-\ point\\:\\ 0\\.06708501865706468\ \(0\)\
\-\ suggestive\\:\\ 0\\.06608044246317916\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.06560356256338105\ \(0\)\
\-\ etiology\\:\\ 0\\.06537098651361252\ \(0\)\
\-\ inflammation\\:\\ 0\\.06521802176188846\ \(0\)\
\-\ outside\\:\\ 0\\.06514215179621304\ \(0\)\
\-\ shortness\\:\\ 0\\.06506668432561719\ \(0\)\
\-\ osseous\\:\\ 0\\.0647687554291771\ \(0\)\
\-\ films\\:\\ 0\\.06426193799085889\ \(0\)\
\-\ tissues\\:\\ 0\\.06398023403612114\ \(0\)\
\-\ with\\:\\ 0\\.06355910265096085\ \(0\)\
\-\ lymph\\:\\ 0\\.06310141496431822\ \(0\)\
\-\ enlargement\\:\\ 0\\.062212026321597294\ \(0\)\
\-\ third\\:\\ 0\\.061787350461463934\ \(0\)\
\-\ pleural\\:\\ 0\\.06108759046922648\ \(0\)\
\-\ structures\\:\\ 0\\.060974238595829997\ \(0\)\
\-\ classic\\:\\ 0\\.060694748567615135\ \(0\)\
\-\ in\\:\\ 0\\.060560900744073054\ \(0\)\
\-\ effusion\\:\\ 0\\.06025868117293622\ \(0\)\
\-\ cardiac\\:\\ 0\\.06025868117293622\ \(0\)\
\-\ active\\:\\ 0\\.06025868117293622\ \(0\)\
\-\ radiographic\\:\\ 0\\.06020510075236535\ \(0\)\
\-\ lungs\\:\\ 0\\.059887788306333956\ \(0\)\
\-\ breath\\:\\ 0\\.05947542364112224\ \(0\)\
\-\ being\\:\\ 0\\.056547057778710386\ \(0\)\
\-\ or\\:\\ 0\\.056459827247981875\ \(0\)\
\-\ followed\\:\\ 0\\.05479819729249502\ \(0\)\
\-\ first\\:\\ 0\\.05476167458990681\ \(0\)\
\-\ unremarkable\\:\\ 0\\.05440151396435985\ \(0\)\
\-\ surrounding\\:\\ 0\\.0541198100096221\ \(0\)\
\-\ right\\:\\ 0\\.05380778076214317\ \(0\)\
\-\ plain\\:\\ 0\\.05353909326306913\ \(0\)\
\-\ positive\\:\\ 0\\.05347230635708982\ \(0\)\
\-\ radiograph\\:\\ 0\\.05285299639162982\ \(0\)\
\-\ radiographs\\:\\ 0\\.052631458891240566\ \(0\)\
\-\ will\\:\\ 0\\.05222896718350802\ \(0\)\
\-\ onset\\:\\ 0\\.05210738024808157\ \(0\)\
\-\ during\\:\\ 0\\.05139890597136273\ \(0\)\
\-\ some\\:\\ 0\\.05105747554581471\ \(0\)\
\-\ treated\\:\\ 0\\.05053309782277798\ \(0\)\
\-\ demonstrated\\:\\ 0\\.04987132339341529\ \(0\)\
\-\ syndrome\\:\\ 0\\.048920930994673734\ \(0\)\
\-\ appearance\\:\\ 0\\.048920930994673734\ \(0\)\
\-\ abnormal\\:\\ 0\\.04875257891333248\ \(0\)\
\-\ lymphoma\\:\\ 0\\.04832860626310777\ \(0\)\
\-\ presented\\:\\ 0\\.047320865898344916\ \(0\)\
\-\ patients\\:\\ 0\\.04565013846061443\ \(0\)\
\-\ more\\:\\ 0\\.044558883041924215\ \(0\)\
\-\ soft\\:\\ 0\\.04320142151774326\ \(0\)\
\-\ most\\:\\ 0\\.04223183066476774\ \(0\)\
\-\ demonstrate\\:\\ 0\\.04218655025037574\ \(0\)\
\-\ other\\:\\ 0\\.042141413507555896\ \(0\)\
\-\ it\\:\\ 0\\.04153848194486368\ \(0\)\
\-\ demonstrates\\:\\ 0\\.04076782856473921\ \(0\)\
\-\ had\\:\\ 0\\.04043087333150388\ \(0\)\
\-\ seen\\:\\ 0\\.03820377991708769\ \(0\)\
\-\ which\\:\\ 0\\.036898762956869\ \(0\)\
\-\ be\\:\\ 0\\.03291846376962825\ \(0\)\
\-\ from\\:\\ 0\\.03222851032066606\ \(0\)\
\-\ are\\:\\ 0\\.03079194200780992\ \(0\)\
\-\ at\\:\\ 0\\.03065059365695203\ \(0\)\
\-\ was\\:\\ 0\\.028280850723807305\ \(0\)\
\-\ this\\:\\ 0\\.02788388390736802\ \(0\)\
\-\ no\\:\\ 0\\.026388377612948263\ \(0\)\
